Wednesday, October 14, 2026
23.7 C
Bengaluru

Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?

India’s diagnostics market is undergoing a quiet but profound shift as at-home testing, e-pharmacies and quick commerce collide on the patient’s smartphone screen. From Zepto’s partnership with Orange Health Labs to Apollo 24/7’s omnichannel diagnostics network and PharmEasy’s Thyrocare-powered home collection, the lab now comes to the consumer instead of the other way around. This convergence is reshaping competitive dynamics for pharma companies, payers and health systems that depend on diagnostics as the front door to care.[1][2][3][4][5]

India’s at-home diagnostics moment

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy,...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

The next owner of an Indian hospital may not...

Indian Pharma’s Three Deficits—and Three Potential Dividends

Indian pharma has already done the hard thing once. It...

Topics

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...

Indian Pharma Is Two Industries Wearing One Label

Indian pharma is often discussed as one sector. In...

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...
spot_img

Related Articles

spot_imgspot_img